Overview

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the potential of adalimumab to inhibit radiographic progression in joint destruction compared with placebo in adult Japanese subjects with recent onset of rheumatoid arthritis.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Collaborator:
Eisai Co., Ltd.
Treatments:
Adalimumab